# A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Source: https://onco.cc/trials/nct07222488/  
OnCo record `nct07222488` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MK-3120 in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) is a phase 1/2 interventional study registered as NCT07222488 by Merck Sharp & Dohme LLC, with 45 participants planned, started 2025-12-09 and due to reach its primary completion in 2029-02-28. Interventions recorded: MK-3120.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07222488
- Phase: 1/2
- Setting: Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07222488: https://clinicaltrials.gov/study/NCT07222488

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07222488.json